Mereo BioPharma Group PLC (MREO) has a current Price-to-Book (P/B) ratio of 1.74. Compared to its 3-year average P/B ratio of 6.27, the current P/B ratio is approximately -72.21% higher. Relative to its 5-year average P/B ratio of 4.21, the current P/B ratio is about -58.62% higher. Mereo BioPharma Group PLC (MREO) has a Forward Free Cash Flow (FCF) yield of approximately -40.30%. Compared to its 3-year average FCF yield of -12.97%, the current FCF yield is approximately 210.61% lower. Relative to its 5-year average FCF yield of -16.05%, the current FCF yield is about 150.99% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MREO competitors is 3.26, providing a benchmark for relative valuation. Mereo BioPharma Group PLC Corp (MREO.O) exhibits a P/S ratio of 4.64, which is 42.17% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MREO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MREO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MREO currently overvalued or undervalued?

What is Mereo BioPharma Group PLC (MREO) fair value?

MREO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Mereo BioPharma Group PLC (MREO) is between 0.08 to 1.40 according to relative valuation method.

How does MREO's valuation metrics compare to the industry average?

The average P/S ratio for MREO's competitors is 3.26, providing a benchmark for relative valuation. Mereo BioPharma Group PLC Corp (MREO) exhibits a P/S ratio of 4.64, which is 42.17% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Mereo BioPharma Group PLC (MREO) as of Mar 03 2026?

As of Mar 03 2026, Mereo BioPharma Group PLC (MREO) has a P/B ratio of 1.74. This indicates that the market values MREO at 1.74 times its book value.

What is the current FCF Yield for Mereo BioPharma Group PLC (MREO) as of Mar 03 2026?

As of Mar 03 2026, Mereo BioPharma Group PLC (MREO) has a FCF Yield of -40.30%. This means that for every dollar of Mereo BioPharma Group PLC's market capitalization, the company generates -40.30 cents in free cash flow.

What is the current Forward P/E ratio for Mereo BioPharma Group PLC (MREO) as of Mar 03 2026?

As of Mar 03 2026, Mereo BioPharma Group PLC (MREO) has a Forward P/E ratio of -15.80. This means the market is willing to pay $-15.80 for every dollar of Mereo BioPharma Group PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mereo BioPharma Group PLC (MREO) as of Mar 03 2026?

As of Mar 03 2026, Mereo BioPharma Group PLC (MREO) has a Forward P/S ratio of 4.64. This means the market is valuing MREO at $4.64 for every dollar of expected revenue over the next 12 months.

MREO Valuation